Latest

psychopharmacology

·July 10, 2025·7 min read

Most Antidepressant Users Don’t Face Severe Withdrawal

The largest review of antidepressant withdrawal studies shows most people don’t experience severe symptoms when stopping these medications. Analyzing data from nearly 18,000 participants, researchers found the most common withdrawal symptoms were mild, including dizziness, nausea, and nervousness.

This shows a psychedelic brain and mushrooms.

Featured Neuroscience

·July 9, 2025·4 min read

Psilocybin Shows Promise as Anti-Aging Therapy

Psilocybin, the active compound derived from psychedelic mushrooms, significantly delayed cellular aging and extended lifespan in a preclinical study. Researchers observed a 50% increase in the lifespan of human skin and lung cells and a 30% increase in survival in aged mice treated with psilocybin.

Featured Neuroscience Psychology

·July 7, 2025·5 min read

Timing of Prozac Treatment Shapes Lasting Mood, Brain Changes

New research reveals that the developmental timing of fluoxetine (Prozac) treatment profoundly influences long-term mood and brain function. In a rodent model, early postnatal treatment in males led to persistent anxiety and depression-like behaviors, while adolescent treatment reduced these behaviors.

This shows the outline of two boys and leaves.

Autism Featured Neuroscience

·June 23, 2025·4 min read

CBD Shows Promise in Easing Behavior Challenges in Autism

Summary: A new clinical trial found that cannabidiol (CBD) is safe and potentially helpful in reducing problematic behaviors in boys with severe autism. While broad behavioral measures showed no significant differences from placebo, clinicians observed meaningful improvements in aggression, hyperactivity, and communication in many children taking CBD.

Featured Neuroscience Psychology

·June 20, 2025·6 min read

Ketamine Plus Therapy Offers Lasting Relief for Severe Depression

A first-of-its-kind clinical trial shows that ketamine treatment for severe, treatment-resistant depression is significantly more effective when paired with psychotherapy and supportive environments. Patients who underwent this combined treatment reported a 30% drop in depression symptoms, with reduced anxiety and suicidal thoughts lasting at least eight weeks.

Featured Neuroscience Psychology

·June 19, 2025·6 min read

Gut Microbiome May Influence Bipolar Medication Response

A new review has examined how bipolar disorder medications interact with the gut microbiome, revealing important links between treatment response and gut microbial composition. Researchers analyzed 12 studies comparing the microbiomes of treated, untreated, and healthy individuals.

Featured Neuroscience Psychology

·June 10, 2025·4 min read

Psilocybin Elevates Spiritual Awareness

Psilocybin significantly enhances psychological well-being and spiritual insight among clergy members across major world religions. Participants reported lasting positive changes in religious practice, personal beliefs, and vocational effectiveness after two guided psilocybin sessions.

This shows people and a swirly background.

Featured Neuroscience Psychology

·June 4, 2025·6 min read

Hallucinogens Linked to Milder PTSD

In a unique real-world study, researchers examined the psychological effects of trauma on survivors of the October 7 Nova Festival attack in Israel, focusing on their use of mind-altering substances. Among 343 participants, those who had taken classic psychedelics like LSD or psilocybin reported significantly lower anxiety and PTSD symptoms than those who used other substances or none at all.

Featured Neuroscience

·June 3, 2025·7 min read

Ibudilast Fails to Beat Placebo in Alcoholism Trial, Except in Women

A recent clinical trial found that ibudilast, a drug once promising for alcohol use disorder, was no more effective than a placebo overall. While all participants reduced their drinking, women on ibudilast showed a greater drop in drinks per day, hinting at a gender-specific benefit.

Featured Neuroscience Psychology

·June 3, 2025·5 min read

Can Chatbots Spot Mental Health Drug Side Effects?

As mental healthcare gaps persist, people increasingly turn to AI chatbots for help with psychiatric medication side effects. A new study evaluated how well large language models detect and respond to these complex, high-risk situations. While AI often mirrors a psychiatrist's tone, researchers found it struggles with accurately identifying adverse drug reactions and offering actionable advice.

Featured Neurology Neuroscience

·May 30, 2025·4 min read

SSRIs Restore Brain Function in Alzheimer’s

A new study suggests that SSRIs, commonly prescribed antidepressants, may reduce biological markers of Alzheimer’s disease. In a cohort of 191 individuals, AD patients on SSRIs had lower levels of plasma phosphorylated tau-181, a key indicator of disease severity.

Featured Neuroscience Psychology

·May 24, 2025·4 min read

Boosting Ketamine’s Antidepressant Effects to Last Two Months

Ketamine is a fast-acting antidepressant that can relieve symptoms of major depressive disorder (MDD) within hours, even in treatment-resistant cases. However, its effects typically last only a week, and frequent dosing poses risks like dissociation or addiction.